Abstract
Cancer immunotherapy, a new weapon against cancers by harnessing the patient's own immune system, potentiates an extended remission and possibly a cure for cancer. T cells genetically engineered with chimeric antigen receptor (CAR) vectors can specifically target the surface antigen of cancer cells and kill them in an MHC-independent manner. CD19 is extensively expressed on cancerous cells in B cell malignancies. To target this antigen, CAR T cells have gained great success in treating patients with B cell leukemia and lymphoma. Currently, the data from clinical trials on CAR T cells in solid tumors are limited; thus, CAR T cells targeting GD2, HER2, EGFRvIII, CSPG4, DNAX, mesothelin, and other molecules are under active investigation for solid tumors. In this review, we summarize the clinical results for CAR T cells in the case of hematologic and solid tumors, along with the current developments in CAR T cell immunotherapy.
Keywords: Cancer immunotherapy, CAR T cells, hematologic malignancies, solid tumor, cancer cells, leukemia.
Current Stem Cell Research & Therapy
Title:Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer
Volume: 13 Issue: 5
Author(s): Feng Li, Tengfei Zhang, Ling Cao and Yi Zhang*
Affiliation:
- Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan,China
Keywords: Cancer immunotherapy, CAR T cells, hematologic malignancies, solid tumor, cancer cells, leukemia.
Abstract: Cancer immunotherapy, a new weapon against cancers by harnessing the patient's own immune system, potentiates an extended remission and possibly a cure for cancer. T cells genetically engineered with chimeric antigen receptor (CAR) vectors can specifically target the surface antigen of cancer cells and kill them in an MHC-independent manner. CD19 is extensively expressed on cancerous cells in B cell malignancies. To target this antigen, CAR T cells have gained great success in treating patients with B cell leukemia and lymphoma. Currently, the data from clinical trials on CAR T cells in solid tumors are limited; thus, CAR T cells targeting GD2, HER2, EGFRvIII, CSPG4, DNAX, mesothelin, and other molecules are under active investigation for solid tumors. In this review, we summarize the clinical results for CAR T cells in the case of hematologic and solid tumors, along with the current developments in CAR T cell immunotherapy.
Export Options
About this article
Cite this article as:
Li Feng , Zhang Tengfei , Cao Ling and Zhang Yi *, Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer, Current Stem Cell Research & Therapy 2018; 13 (5) . https://dx.doi.org/10.2174/1574888X13666180420110239
DOI https://dx.doi.org/10.2174/1574888X13666180420110239 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Telomerase Inhibitors as Anticancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents MDR Reversal by Deprenylated Tetracyclic and Hexacyclic Analogues of N-Acetylardeemin: Confirmation of the Ardeemin Pharmacophore
Letters in Drug Design & Discovery Targeted Therapy for Advanced Renal Cell Cancer: Cytokines and Beyond
Current Pharmaceutical Design Progress in the Discovery of Macrocyclic Histone Deacetylase Inhibitors for the Treatment of Cancer
Current Medicinal Chemistry Integrins as Novel Drug Targets for Overcoming Innate Drug Resistance
Current Cancer Drug Targets Interaction of Biologically Active Amines with Mitochondria and Their Role in the Mitochondrial-Mediated Pathway of Apoptosis
Current Medicinal Chemistry Antiangiogenic Resistance and Cancer Metabolism: Opportunities for Synthetic Lethality
Current Drug Targets MicroRNAs in Colorectal Neoplasia: From Pathobiology to Clinical Applications
Current Pharmaceutical Biotechnology TGF-beta Signaling in Cancer Treatment
Current Pharmaceutical Design Genetic Variation at the Human MGMT Locus and its Biological Consequences
Current Pharmacogenomics Role of miRNAs in Coronary Artery Disease
Current Signal Transduction Therapy Molecular Targets of Gemcitabine Action: Rationale for Development of Novel Drugs and Drug Combinations
Current Pharmaceutical Design Cellular Targets for Anticancer Strategies
Current Drug Targets MDM2-p53 Interaction in Paediatric Solid Tumours: Preclinical Rationale, Biomarkers and Resistance
Current Drug Targets Targeting Stem Cells-Clinical Implications for Cancer Therapy
Current Stem Cell Research & Therapy Medicinal Research Progress of Natural Coumarin and its Derivatives
The Natural Products Journal Natural Product-Derived Small Molecule Activators of Hypoxia-Inducible Factor-1 (HIF-1)
Current Pharmaceutical Design Osteoclast Apoptosis in Rheumatic Diseases Characterized by a High Level of Bone Resorption (Osteoporosis, Rheumatoid Arthritis, Myeloma and Pagets Disease of Bone)
Current Rheumatology Reviews Dynamics of Telomere Length in Different Age Groups in a Latvian Population
Current Aging Science miRNA as an Ultimate and Emerging Diagnostic Approach for the Detection of Alzheimer’s Disease
MicroRNA